KNSA

Dollar change -0.71
Percentage change -2.47	%

Peers: AMGN REGN BIIB VRTX GILD INCY BMRN NBIX EXEL SAGE

| Held by: VTI VB VBK VTWO VHT FESM DFAS DFAC SFLO VTWG

Index	-	P/E	-	EPS (ttm)	-0.24	Insider Own	44.55%	Shs Outstand	42.16M	Perf Week	3.23%
Market Cap	2.05B	Forward P/E	21.10	EPS next Y	1.33	Insider Trans	-1.90%	Shs Float	40.47M	Perf Month	1.30%
Enterprise Value	1.79B	PEG	-	EPS next Q	0.19	Inst Own	55.80%	Short Float	5.11%	Perf Quarter	45.47%
Income	-16.95M	P/S	4.26	EPS this Y	233.79%	Inst Trans	9.75%	Short Ratio	2.64	Perf Half Y	40.94%
Sales	481.17M	P/B	4.47	EPS next Y	65.85%	ROA	-3.03%	Short Interest	2.07M	Perf YTD	42.01%
Book/sh	6.28	P/C	7.64	EPS next 5Y	-	ROE	-3.81%	52W High	30.69 -8.47%	Perf Year	30.05%
Cash/sh	3.68	P/FCF	46.87	EPS past 3/5Y	35.96% 27.38%	ROIC	-3.64%	52W Low	17.82 57.63%	Perf 3Y	153.75%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	122.27% -	Gross Margin	54.31%	Volatility	3.59% 3.50%	Perf 5Y	20.71%
Dividend TTM	-	EV/Sales	3.72	EPS Y/Y TTM	-290.38%	Oper. Margin	-3.28%	ATR (14)	1.04	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.43	Sales Y/Y TTM	59.45%	Profit Margin	-3.52%	RSI (14)	50.47	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.66	EPS Q/Q	144.73%	SMA20	-0.31%	Beta	0.13	Target Price	40.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	72.54%	SMA50	1.21%	Rel Volume	0.51	Prev Close	28.80
Employees	315	LT Debt/Eq	0.02	Earnings	Apr 29 BMO	SMA200	20.76%	Avg Volume	783.32K	Price	28.09
IPO	May 24, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-14.79% 4.48%	Trades		Volume	404,501	Change	-2.47%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-25	Initiated	Citigroup	Buy	$40
Sep-13-24	Initiated	Jefferies	Buy	$40
May-03-24	Initiated	Wells Fargo	Overweight	$34
Jun-29-20	Reiterated	BofA Securities	Buy	$25 → $40
Apr-01-20	Initiated	BofA/Merrill	Buy	$25
Mar-11-19	Initiated	Barclays	Overweight	$26
Dec-12-18	Reiterated	Wedbush	Outperform	$31 → $33
Jun-19-18	Initiated	JMP Securities	Mkt Outperform	$33

Jul-03-25 08:42AM	Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore (Zacks)
Jul-02-25 07:00PM	Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth (Motley Fool)
09:28AM	5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment (Zacks)
Jul-01-25 01:38PM	Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Strong Tailwind (Investor's Business Daily)
01:37PM	Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind (Investor's Business Daily)
07:00AM	Loading…
Jun-05-25 07:00AM	Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis (GlobeNewswire)
May-29-25 04:01PM	Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-05-25 04:51PM	Kiniksa Pharmaceuticals: Making Steady Progress (Seeking Alpha)
Apr-30-25 08:30AM	Kiniksa Pharmaceuticals Announces GRAMMY Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis (GlobeNewswire)
Apr-29-25 03:07PM	Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript (Seeking Alpha) +20.54%
08:35AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates (Zacks)
07:30AM	Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution (GlobeNewswire)
02:10AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2025: Everything You Need To Know Ahead Of ... (GuruFocus.com)
02:10AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Apr-24-25 04:01PM	Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025 (GlobeNewswire)
07:21AM	Loading…
Apr-22-25 07:21AM	Cardiol Therapeutics Stock: Is Cannabis Potential Priced In? (Zacks)
Apr-21-25 09:54AM	uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? (Zacks)
Apr-10-25 09:31AM	Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar? (Zacks) -6.28%
Apr-08-25 09:40AM	Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-04-25 09:55AM	Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know (Zacks) -6.43%
Mar-27-25 08:35AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Mar-19-25 09:55AM	How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6% (Zacks)
Mar-14-25 05:51AM	3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now (Motley Fool)
Mar-06-25 08:23AM	Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now? (Insider Monkey)
Mar-04-25 12:20PM	Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock (Zacks)
03:05AM	Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock? (Zacks)
Mar-03-25 09:55AM	Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High? (Zacks) +5.82%
Mar-02-25 11:58AM	Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-25-25 08:45AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution (GlobeNewswire)
07:29AM	Loading…
07:29AM	Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy (GlobeNewswire)
Feb-20-25 04:01PM	Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 (GlobeNewswire)
Feb-10-25 10:32AM	Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles (The Wall Street Journal)
Jan-13-25 07:30AM	Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance (GlobeNewswire) -8.83%
Jan-06-25 04:01PM	Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-26-24 04:01PM	Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-13-24 10:45AM	Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025? (Insider Monkey)
Nov-12-24 04:01PM	Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Oct-30-24 04:25AM	Q3 2024 Kiniksa Pharmaceuticals Ltd Earnings Call (Thomson Reuters StreetEvents)
03:07AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings Call Highlights: Impressive ... (GuruFocus.com)
Oct-29-24 08:45AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -15.68%
07:30AM	Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Oct-28-24 09:05AM	What To Expect From Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings (GuruFocus.com)
08:00AM	Kiniksa Pharmaceuticals Partners with GRAMMY Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted Campaign to Drive Awareness of Recurrent Pericarditis (GlobeNewswire)
Oct-22-24 04:01PM	Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024 (GlobeNewswire)
Oct-09-24 09:55AM	Wall Street Analysts Think Kiniksa Pharmaceuticals (KNSA) Could Surge 42.34%: Read This Before Placing a Bet (Zacks)
Oct-08-24 09:10PM	Baker Bros. Advisors LP Increases Stake in Kiniksa Pharmaceuticals (GuruFocus.com)
Oct-01-24 08:00AM	NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted Campaign to Drive Awareness of Recurrent Pericarditis (GlobeNewswire)
Aug-28-24 04:01PM	Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-05-24 09:55AM	Wall Street Analysts Believe Kiniksa Pharmaceuticals (KNSA) Could Rally 30.11%: Here's is How to Trade (Zacks)
Jul-26-24 12:00PM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Is Up 0.09% in One Week: What You Should Know (Zacks)
08:50AM	Recent Price Trend in Kiniksa Pharmaceuticals (KNSA) is Your Friend, Here's Why (Zacks)
Jul-23-24 08:35AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +22.91%
07:30AM	Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Jul-16-24 04:01PM	Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024 (GlobeNewswire)
Jul-09-24 08:00AM	Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjogren's Disease (GlobeNewswire)
08:00AM	Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sj gren's Disease (GlobeNewswire)
Jun-24-24 08:00AM	Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis (GlobeNewswire)
Jun-17-24 08:30AM	Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative (GlobeNewswire)
Jun-04-24 04:01PM	Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-24 07:00AM	Sector Spotlight: Orphan Drug Developers With Significant Upside (News Direct)
May-07-24 04:01PM	Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference (GlobeNewswire)
Apr-24-24 09:00AM	Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-23-24 11:53AM	KNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:53AM	Kiniksa Pharmaceuticals Ltd (KNSA) Q1 2024 Earnings Overview: Surpasses Revenue Forecasts (GuruFocus.com)
08:40AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:36AM	Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises (MT Newswires)
07:30AM	Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Apr-16-24 04:01PM	Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024 (GlobeNewswire)
Apr-02-24 07:30AM	Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart (GlobeNewswire)
Mar-01-24 09:55AM	Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect? (Zacks)
Feb-29-24 11:33PM	Chief Medical Officer John Paolini Sells 10,156 Shares of Kiniksa Pharmaceuticals Ltd (KNSA) (GuruFocus.com)
12:00PM	Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choice (Zacks)
09:21AM	Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 08:50AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
08:40AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:52AM	Kiniksa Pharmaceuticals Ltd (KNSA) Reports Strong Revenue Growth in Q4 and Full-Year 2023 (GuruFocus.com)
07:30AM	Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Feb-21-24 04:01PM	Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-12-24 09:55AM	Wall Street Analysts Predict a 38.07% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know (Zacks)
08:50AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jan-23-24 09:55AM	How Much Upside is Left in Kiniksa Pharmaceuticals, Ltd. (KNSA)? Wall Street Analysts Think 43.93% (Zacks)
08:50AM	Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's Why (Zacks)
Jan-09-24 08:46AM	Is Kiniksa Pharmaceuticals (KNSA) Stock a Solid Choice Right Now? (Zacks)
Jan-04-24 07:30AM	Kiniksa Pharmaceuticals Provides Corporate Update (GlobeNewswire)
Jan-02-24 04:01PM	Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +5.64% +7.83%
Dec-23-23 09:00AM	Chief Accounting Officer Michael Megna Sells 9,316 Shares of Kiniksa Pharmaceuticals Ltd (KNSA) (GuruFocus.com)
Dec-15-23 02:30PM	The 3 Most Undervalued Biotech Stocks to Buy in December (InvestorPlace) +5.51%
Nov-24-23 02:05PM	Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How (Zacks)
Nov-20-23 09:55AM	Wall Street Analysts See a 70.27% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High? (Zacks)
Nov-09-23 10:01PM	7 Underappreciated Biotech Stocks to Pick Up on the Cheap (InvestorPlace) -5.83%
Nov-01-23 08:27AM	Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-31-23 10:48PM	Q3 2023 Kiniksa Pharmaceuticals Ltd Earnings Call (Thomson Reuters StreetEvents)
08:50AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Oct-24-23 04:01PM	Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023 (GlobeNewswire)
Oct-20-23 12:08PM	12 Cheap Biotech Stocks Smart Investors Are Piling Into (Insider Monkey)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Aug-27-23 08:40AM	13 NASDAQ Stocks with Lowest PE Ratios That May Not Be Value Traps (Insider Monkey)
Aug-22-23 08:14AM	11 Most Undervalued Biotech Stocks to Buy According to Analysts (Insider Monkey)

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tessari Eben	Officer	Jul 14 '25	Proposed Sale	28.72	18,900	542,860		Jul 14 05:04 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jun 16 '25	Option Exercise	8.83	6,500	57,395	78,863	Jun 18 04:39 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jun 16 '25	Sale	28.28	17,300	489,244	61,563	Jun 18 04:39 PM
Tessari Eben	Officer	Jun 16 '25	Proposed Sale	28.28	17,300	489,171		Jun 16 05:23 PM
Quart Barry D	Director	Jun 11 '25	Option Exercise	3.80	12,336	46,877	24,882	Jun 11 05:35 PM
Quart Barry D	Director	Jun 10 '25	Option Exercise	3.80	8,212	31,206	20,758	Jun 11 05:35 PM
Quart Barry D	Director	Jun 09 '25	Option Exercise	3.80	6,900	26,220	19,446	Jun 11 05:35 PM
Quart Barry D	Director	Jun 11 '25	Sale	30.39	12,336	374,891	12,546	Jun 11 05:35 PM
Quart Barry D	Director	Jun 10 '25	Sale	30.36	8,212	249,316	12,546	Jun 11 05:35 PM
Quart Barry D	Director	Jun 09 '25	Sale	30.26	6,900	208,794	12,546	Jun 11 05:35 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jun 11 '25	Option Exercise	10.36	45,042	466,635	117,405	Jun 11 05:32 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jun 10 '25	Option Exercise	10.36	15,506	160,642	87,869	Jun 11 05:32 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jun 09 '25	Option Exercise	10.36	10,319	106,905	82,682	Jun 11 05:32 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jun 11 '25	Sale	30.51	45,042	1,374,231	72,363	Jun 11 05:32 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jun 10 '25	Sale	30.46	15,506	472,313	72,363	Jun 11 05:32 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jun 09 '25	Sale	30.38	10,319	313,491	72,363	Jun 11 05:32 PM
Tessari Eben	Officer	Jun 11 '25	Proposed Sale	30.51	45,042	1,374,277		Jun 11 04:39 PM
Tessari Eben	Officer	Jun 10 '25	Proposed Sale	30.46	15,506	472,239		Jun 10 05:46 PM
Tessari Eben	Officer	Jun 09 '25	Proposed Sale	30.38	10,319	313,453		Jun 09 05:09 PM
Quart Barry D	Director	Jun 09 '25	Proposed Sale	30.26	27,448	830,576		Jun 09 05:08 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Jun 03 '25	Option Exercise	15.50	15,211	235,770	47,757	Jun 05 04:50 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Jun 03 '25	Sale	28.75	15,211	437,316	32,546	Jun 05 04:50 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	Jun 03 '25	Option Exercise	13.35	27,594	368,380	37,009	Jun 05 04:46 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	Jun 03 '25	Sale	29.02	27,594	800,778	9,415	Jun 05 04:46 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Jun 03 '25	Option Exercise	18.00	18,299	329,382	45,308	Jun 05 04:38 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Jun 03 '25	Sale	28.80	18,299	527,011	27,009	Jun 05 04:38 PM
Megna Michael R	Officer	Jun 03 '25	Proposed Sale	28.75	15,211	437,330		Jun 03 04:36 PM
Moat Ross	Officer	Jun 03 '25	Proposed Sale	29.02	27,594	800,914		Jun 03 04:35 PM
Ragosa Mark	Officer	Jun 03 '25	Proposed Sale	28.80	18,299	527,011		Jun 03 04:34 PM
Patel Sanj K	CHAIRMAN & CEO	May 28 '25	Option Exercise	1.59	62,116	98,764	158,790	May 28 05:25 PM
Patel Sanj K	CHAIRMAN & CEO	May 27 '25	Option Exercise	1.59	19,317	30,714	115,991	May 28 05:25 PM
Patel Sanj K	CHAIRMAN & CEO	May 23 '25	Option Exercise	1.59	4,837	7,691	101,511	May 28 05:25 PM
Patel Sanj K	CHAIRMAN & CEO	May 28 '25	Sale	27.33	62,116	1,697,630	96,674	May 28 05:25 PM
Patel Sanj K	CHAIRMAN & CEO	May 27 '25	Sale	27.01	19,317	521,752	96,674	May 28 05:25 PM
Patel Sanj K	CHAIRMAN & CEO	May 23 '25	Sale	27.00	4,837	130,599	96,674	May 28 05:25 PM
Patel Sanj K	CHAIRMAN & CEO	May 20 '25	Option Exercise	1.59	2,349	3,735	99,023	May 22 04:38 PM
Patel Sanj K	CHAIRMAN & CEO	May 20 '25	Sale	27.02	2,349	63,470	96,674	May 22 04:38 PM
Tessari Eben	CHIEF OPERATING OFFICER	May 19 '25	Option Exercise	3.80	7,000	26,600	84,363	May 21 04:37 PM
Tessari Eben	CHIEF OPERATING OFFICER	May 19 '25	Sale	26.41	12,000	316,920	72,363	May 21 04:37 PM
Tessari Eben	Officer	May 19 '25	Proposed Sale	26.41	12,000	316,898		May 19 05:16 PM
Patel Sanj K	CHAIRMAN & CEO	May 13 '25	Option Exercise	1.59	2,872	4,566	99,546	May 15 04:39 PM
Patel Sanj K	CHAIRMAN & CEO	May 13 '25	Sale	27.03	2,872	77,630	96,674	May 15 04:39 PM
Patel Sanj K	CHAIRMAN & CEO	May 09 '25	Option Exercise	1.59	6,029	9,586	102,703	May 09 05:32 PM
Patel Sanj K	CHAIRMAN & CEO	May 07 '25	Option Exercise	1.59	1,965	3,124	98,639	May 09 05:32 PM
Patel Sanj K	CHAIRMAN & CEO	May 08 '25	Option Exercise	1.59	101	161	96,775	May 09 05:32 PM
Patel Sanj K	CHAIRMAN & CEO	May 09 '25	Sale	27.05	6,029	163,084	96,674	May 09 05:32 PM
Patel Sanj K	CHAIRMAN & CEO	May 07 '25	Sale	27.00	1,965	53,055	96,674	May 09 05:32 PM
Patel Sanj K	CHAIRMAN & CEO	May 08 '25	Sale	27.00	101	2,727	96,674	May 09 05:32 PM
Paolini John F.	CHIEF MEDICAL OFFICER	May 07 '25	Option Exercise	3.80	200	760	57,603	May 09 05:01 PM
Paolini John F.	CHIEF MEDICAL OFFICER	May 07 '25	Sale	27.00	200	5,400	57,403	May 09 05:01 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	May 07 '25	Option Exercise	12.53	17,647	221,098	50,193	May 09 04:59 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	May 07 '25	Sale	26.69	17,647	470,998	32,546	May 09 04:59 PM
Patel Sanj K	Officer	May 07 '25	Proposed Sale	27.00	99,586	2,688,822		May 07 05:13 PM
Paolini John F.	Officer	May 07 '25	Proposed Sale	27.00	29,525	797,175		May 07 04:59 PM
Megna Michael R	Officer	May 07 '25	Proposed Sale	26.69	17,647	471,014		May 07 04:00 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	May 05 '25	Option Exercise	17.76	6,272	111,391	15,687	May 05 04:54 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	May 02 '25	Option Exercise	17.76	3,850	68,376	13,265	May 05 04:54 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	May 05 '25	Sale	28.00	6,272	175,616	9,415	May 05 04:54 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	May 02 '25	Sale	28.00	3,850	107,800	9,415	May 05 04:54 PM
Moat Ross	Officer	May 05 '25	Proposed Sale	28.00	6,272	175,646		May 05 04:11 PM
Moat Ross	Officer	May 02 '25	Proposed Sale	28.01	3,850	107,829		May 02 05:01 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	Apr 29 '25	Option Exercise	13.71	64,035	878,123	73,450	May 01 06:26 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	May 01 '25	Option Exercise	12.73	23,234	295,767	32,649	May 01 06:26 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	Apr 29 '25	Sale	25.21	64,035	1,614,322	9,415	May 01 06:26 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	May 01 '25	Sale	28.02	23,234	651,017	9,415	May 01 06:26 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Apr 29 '25	Option Exercise	15.51	42,000	651,400	69,009	May 01 06:24 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	May 01 '25	Option Exercise	17.84	25,141	448,424	52,150	May 01 06:24 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Apr 30 '25	Option Exercise	16.90	21,254	359,193	48,263	May 01 06:24 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Apr 29 '25	Sale	25.61	42,000	1,075,620	27,009	May 01 06:24 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	May 01 '25	Sale	27.80	25,141	698,920	27,009	May 01 06:24 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Apr 30 '25	Sale	26.95	21,254	572,795	27,009	May 01 06:24 PM
Ragosa Mark	Officer	May 01 '25	Proposed Sale	27.80	25,141	698,920		May 01 05:11 PM
Moat Ross	Officer	May 01 '25	Proposed Sale	28.02	23,234	650,949		May 01 05:10 PM
Ragosa Mark	Officer	Apr 30 '25	Proposed Sale	26.95	21,254	572,795		Apr 30 04:32 PM
Moat Ross	Officer	Apr 29 '25	Proposed Sale	25.21	64,035	1,614,580		Apr 29 04:29 PM
Ragosa Mark	Officer	Apr 29 '25	Proposed Sale	25.61	42,000	1,075,827		Apr 29 04:29 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	Apr 21 '25	Sale	20.29	18,259	370,475	9,415	Apr 23 04:44 PM
Moat Ross	Officer	Apr 21 '25	Proposed Sale	20.29	18,259	370,422		Apr 21 04:06 PM
Tessari Eben	CHIEF OPERATING OFFICER	Apr 14 '25	Option Exercise	3.80	7,000	26,600	89,363	Apr 16 04:38 PM
Tessari Eben	CHIEF OPERATING OFFICER	Apr 14 '25	Sale	20.48	12,000	245,812	77,363	Apr 16 04:38 PM
Tessari Eben	Officer	Apr 14 '25	Proposed Sale	20.49	12,000	245,852		Apr 14 04:56 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Mar 20 '25	Option Exercise	12.97	15,944	206,794	39,326	Mar 24 04:35 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Mar 20 '25	Sale	23.11	15,944	368,466	23,382	Mar 24 04:35 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Mar 17 '25	Option Exercise	12.97	11,464	148,688	34,846	Mar 19 05:53 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Mar 19 '25	Option Exercise	12.97	8,879	115,161	32,261	Mar 19 05:53 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Mar 17 '25	Sale	23.10	11,464	264,818	23,382	Mar 19 05:53 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Mar 19 '25	Sale	23.10	8,879	205,105	23,382	Mar 19 05:53 PM
Ragosa Mark	Officer	Mar 17 '25	Proposed Sale	23.10	36,287	838,230		Mar 17 05:29 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Mar 12 '25	Option Exercise	11.10	9,051	100,466	35,579	Mar 14 04:38 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Mar 12 '25	Sale	22.45	9,051	203,195	26,528	Mar 14 04:38 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Mar 12 '25	Option Exercise	11.97	36,372	435,373	59,330	Mar 14 04:37 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Mar 12 '25	Sale	22.25	36,372	809,277	22,958	Mar 14 04:37 PM
Megna Michael R	Officer	Mar 12 '25	Proposed Sale	22.45	9,051	203,207		Mar 12 04:47 PM
Tessari Eben	CHIEF OPERATING OFFICER	Mar 10 '25	Option Exercise	3.80	7,000	26,600	88,975	Mar 12 04:37 PM
Tessari Eben	CHIEF OPERATING OFFICER	Mar 10 '25	Sale	21.06	12,409	261,334	76,566	Mar 12 04:37 PM
Ragosa Mark	Officer	Mar 12 '25	Proposed Sale	22.25	36,372	809,405		Mar 12 04:04 PM
Tessari Eben	Officer	Mar 10 '25	Proposed Sale	21.06	12,409	261,330		Mar 10 05:13 PM
Tessari Eben	CHIEF OPERATING OFFICER	Feb 10 '25	Option Exercise	3.80	7,000	26,600	95,975	Feb 12 04:57 PM
Tessari Eben	CHIEF OPERATING OFFICER	Feb 10 '25	Sale	19.57	14,000	273,980	81,975	Feb 12 04:57 PM
Tessari Eben	Officer	Feb 10 '25	Proposed Sale	19.57	14,000	274,041		Feb 10 05:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Kiniksa Pharmaceuticals International Plc

Upgrade your FINVIZ experience